Breaking News Instant updates and real-time market news.

BSX

Boston Scientific

$26.39

-2.12 (-7.44%)

07:26
11/29/17
11/29
07:26
11/29/17
07:26

Boston Scientific speculation worse than actual news, says Cowen

Cowen analyst Joshua Jennings noted Boston Scientific shares were weak yesterday prior to the company announcing another setback to the timelines for the Lotus valve system's European reintroduction and U.S. approval and launch. The analyst believes the speculation prior to the release was worse than the actual announcement and he believes there will be little effect on Q4 or 2017 guidance. However, admittedly, the 2018 impact is unknown at this time. Jennings reiterated his Outperform rating and $32 price target on Boston Scientific shares.

  • 01

    Dec

  • 14

    Dec

BSX Boston Scientific
$26.39

-2.12 (-7.44%)

11/28/17
SBSH
11/28/17
NO CHANGE
Target $34
SBSH
Buy
Citi concerned after Boston Scientific cancels conference presentation
Citi analyst Amit Hazan says he's "unambiguously concerned" about the status of Boston Scientific's Lotus TAVR valve after the company cancelled its presentation at a conference scheduled for today. Boston Scientific confirmed the cancellation with the analyst and noted it would still be appearing at Citi's conference next week. Hazan asked the company if today's cancellation is related to the Lotus TAVR valve and has not heard back. It is now "very fair" to ascribe a higher risk to Lotus timelines, Hazan tells investors in a research note. He views Boston Scientific's lack of response to his question as a "non-denial denial." The analyst notes that he'd value Boston Scientific shares at $27-$28 if Lotus were to be taken completely out of his model. The market is already basically pricing in the elimination of Lotus, Hazan contends. He has a Buy rating on Boston Scientific with a $34 price target. The stock in afternoon trading is down 6% to $26.92.
11/28/17
WELS
11/28/17
NO CHANGE
WELS
Boston Scientific weakness a buying opportunity, says Wells Fargo
11/28/17
WELS
11/28/17
NO CHANGE
WELS
Outperform
Amid Boston Scientific slide, Wells Fargo finds no new issues with Lotus
Wells Fargo analyst Larry Biegelsen notes that weakness in shares of Boston Scientific followed the company having canceled an investor conference appearance, pointing out that the last time this happened the company then announced a recall of its Lotus TAVR device in Europe. While he attributes the pullback to investor worries about "another shoe to drop," his checks have found no new issues with Lotus, Biegelsen tells investors. Even assuming Lotus revenues were completely removed, he sees a floor for Boston Scientific at $26-$27 per share. Biegelsen maintains an Outperform rating on Boston Scientific, which is down nearly 6% to $26.86 in afternoon trading.
11/29/17
JPMS
11/29/17
NO CHANGE
Target $31
JPMS
Overweight
Boston Scientific selloff yesterday a buying opportunity, says JPMorgan
Boston Scientific last night confirmed speculation by announcing additional delays to its Lotus transcatheter valve program, JPMorgan analyst Michael Weinstein tells investors in a research note. The good news is that the delay is internally driven, the analyst notes after speaking to management. He points out that there are no issues at this point with the European notified body or with the FDA. The issue is manufacturing, Weinstein writes. The analyst is a buyer of Boston Scientific following yesterday's selloff. Despite the Lotus delay, he still thinks the company can grow organic sales by 6% in 2018 and 7%-8% in 2019-2020. Weinstein keeps an Overweight rating on Boston Scientific with a $31 price target.

TODAY'S FREE FLY STORIES

KURA

Kura Oncology

$14.90

0.75 (5.30%)

10:07
12/11/17
12/11
10:07
12/11/17
10:07
Hot Stocks
Kura Oncology findings supoort tipifarnib development in bone marrow cancers »

Kura Oncology reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIVV

Bioverativ

$51.47

0.76 (1.50%)

10:05
12/11/17
12/11
10:05
12/11/17
10:05
Hot Stocks
Bioverativ data shows extended dosing with Alprolix provides HepB protection »

Bioverativ and Swedish…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XENT

Intersect ENT

$28.60

-1.325 (-4.43%)

10:05
12/11/17
12/11
10:05
12/11/17
10:05
Recommendations
Intersect ENT analyst commentary  »

Intersect ENT approval…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

CTL

CenturyLink

$15.62

0.9451 (6.44%)

10:04
12/11/17
12/11
10:04
12/11/17
10:04
Technical Analysis
Technical View: CenturyLink higher on Commonwealth of Pennsylvania contract »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMRN

BioMarin

$81.99

1.09 (1.35%)

10:03
12/11/17
12/11
10:03
12/11/17
10:03
Hot Stocks
BioMarin highlights new results for valoctocogene roxaparvovec at ASH »

BioMarin Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

  • 28

    Feb

ABBV

AbbVie

$96.13

0.18 (0.19%)

10:02
12/11/17
12/11
10:02
12/11/17
10:02
Hot Stocks
AbbVie: Ibrutinib inhibited pre-germinal center B cells in trial »

AbbVie announced new data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALXN

Alexion

$114.46

7.68 (7.19%)

10:02
12/11/17
12/11
10:02
12/11/17
10:02
Hot Stocks
Alexion reports results from Phase 1b/2 studies of ALXN1210 »

Alexion Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

10:01
12/11/17
12/11
10:01
12/11/17
10:01
General news
JOLTS Job Openings data reported »

October JOLTS Job…

CELG

Celgene

$106.09

3.36 (3.27%)

10:00
12/11/17
12/11
10:00
12/11/17
10:00
Options
Sizable put spread in Celgene as shares see strength »

Sizable put spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 25

    Mar

MARK

Remark Holdings

$8.84

1.43 (19.30%)

09:59
12/11/17
12/11
09:59
12/11/17
09:59
Conference/Events
Remark Holdings management to meet with Roth Capital »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

CTL

CenturyLink

$15.47

0.795 (5.42%)

, FTR

Frontier Communications

$9.75

0.6 (6.56%)

09:55
12/11/17
12/11
09:55
12/11/17
09:55
Options
Early notable gainers among liquid option names on December 11th »

Notable gainers among…

CTL

CenturyLink

$15.47

0.795 (5.42%)

FTR

Frontier Communications

$9.75

0.6 (6.56%)

SWN

Southwestern Energy

$5.72

0.225 (4.10%)

MNK

Mallinckrodt

$22.64

0.34 (1.52%)

WYNN

Wynn Resorts

$159.54

0.62 (0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

  • 14

    Dec

ECR

Eclipse Resources

$2.36

0.21 (9.77%)

09:55
12/11/17
12/11
09:55
12/11/17
09:55
Conference/Events
Eclipse Resources to hold a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

XLE

Energy Select Sector SPDR

$69.57

0.29 (0.42%)

09:54
12/11/17
12/11
09:54
12/11/17
09:54
Technical Analysis
Technical View: Energy Select Sector SPDR leads on the upside »

The Energy Select Sector…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKE

Nike

$61.50

0.195 (0.32%)

09:51
12/11/17
12/11
09:51
12/11/17
09:51
Upgrade
Nike rating change  »

Follow-up: Nike upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Dec

IBB

iShares Nasdaq Biotechnology Index

$106.07

2.02 (1.94%)

09:50
12/11/17
12/11
09:50
12/11/17
09:50
Technical Analysis
Technical View: iShares Nasdaq Biotechnology Index breaks out »

The iShares Nasdaq…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKS

AK Steel

$5.46

0.13 (2.44%)

09:50
12/11/17
12/11
09:50
12/11/17
09:50
Options
Interest in AK Steel Mar 7 calls continues »

Interest in AK Steel Mar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONCE

Spark Therapeutics

$73.38

2.82 (4.00%)

09:48
12/11/17
12/11
09:48
12/11/17
09:48
Conference/Events
Spark Therapeutics to hold a pharmaceutical update conference call »

Management reviews the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 12

    Jan

NKE

Nike

$61.67

0.365 (0.60%)

09:47
12/11/17
12/11
09:47
12/11/17
09:47
Upgrade
Nike rating change  »

Nike upgraded to Positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Dec

09:45
12/11/17
12/11
09:45
12/11/17
09:45
General news
JOLTS Job Openings to be reported at 10:00 »

October JOLTS Job…

IOTS

Adesto Technologies

$7.00

-0.45 (-6.04%)

09:44
12/11/17
12/11
09:44
12/11/17
09:44
Conference/Events
Adesto Technologies management to meet with Roth Capital »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 14

    Dec

AGIO

Agios Pharmaceuticals

$60.97

0.14 (0.23%)

09:42
12/11/17
12/11
09:42
12/11/17
09:42
Conference/Events
Agios Pharmaceuticals to hold an investor meeting »

Investor Meeting where…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

KMB

Kimberly-Clark

09:41
12/11/17
12/11
09:41
12/11/17
09:41
Technical Analysis
Technical View: Kimberly-Clark falls in early trading, analyst action »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKS

AK Steel

, CELG

Celgene

$106.09

3.36 (3.27%)

09:40
12/11/17
12/11
09:40
12/11/17
09:40
Options
Unusually active option classes on open December 11th »

Unusual total active…

AKS

AK Steel

CELG

Celgene

$106.09

3.36 (3.27%)

GME

GameStop

CTL

CenturyLink

X

U.S. Steel

ORCL

Oracle

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 18

    Jan

  • 25

    Mar

09:40
12/11/17
12/11
09:40
12/11/17
09:40
General news
Fed funds futures are flat to lower ahead of Wednesday's FOMC »

Fed funds futures are…

ECR

Eclipse Resources

09:35
12/11/17
12/11
09:35
12/11/17
09:35
Conference/Events
Eclipse Resources to hold a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.